Chevron CEO Michael Wirth Says $15B Share Buyback Can Be Sustained For ‘Multiple Years’

-Reuters

byBenzinga Newsdesk

September 7, 2022

1 minute read

-Reuters

Seagen Late Sunday Announced Prelim. Results From Phase 2 Trial Of ADCETRIS In Novel Combo Of Agents For Patients With Advanced Stage Classical Hodgkin Lymphoma: Showed ‘Complete Response Rate of 88%, Overall Response Rate of 93%’

By Benzinga Newsdesk

Today, 4:44 AM

– Frontline Treatment with ADCETRIS in Combination with Nivolumab, Doxorubicin and Dacarbazine (AN+AD) Shows a Complete Response Rate of 88%, Overall Response Rate of 93% and Favorable Safety Profile

SGEN

Medtronic Trims FY23 Annual Outlook On Currency Headwind, Posts Mixed Q2 Earnings

By Vandana Singh

Today, 4:44 AM

Medtronic Plc’s (NYSE:MDT) Q2 FY23 sales of $7.58 billion decreased 3% Y/Y on a reported basis and increased 2% organically, missing…

MDT

Credit Suisse Initiates Coverage On AZEK Co with Outperform Rating, Announces Price Target of $29

By Benzinga Newsdesk

Today, 4:44 AM

Credit Suisse analyst Daniel Oppenheim initiates coverage on AZEK Co (NYSE:AZEK) with a Outperform rating and announces Price Target of $29.

AZEK

Needham Initiates Coverage On Braze with Buy Rating, Announces Price Target of $90

By Benzinga Newsdesk

Today, 4:44 AM

Needham analyst Scott Berg initiates coverage on Braze (NASDAQ:BRZE) with a Buy rating and announces Price Target of $90.

BRZE

Chevron CEO Michael Wirth Says $15B Share Buyback Can Be Sustained For ‘Multiple Years’

Related Posts

Seagen Late Sunday Announced Prelim. Results From Phase 2 Trial Of ADCETRIS In Novel Combo Of Agents For Patients With Advanced Stage Classical Hodgkin Lymphoma: Showed ‘Complete Response Rate of 88%, Overall Response Rate of 93%’

Medtronic Trims FY23 Annual Outlook On Currency Headwind, Posts Mixed Q2 Earnings

Credit Suisse Initiates Coverage On AZEK Co with Outperform Rating, Announces Price Target of $29

Needham Initiates Coverage On Braze with Buy Rating, Announces Price Target of $90